

| Product (Active Ingredient) | Additional Indication |
|--|---|
| 1) Azep Nasal Spray | For use in children from 6 years onwards |
| 2) Zyprexa 5mg Tablet, 3) Zyprexa 7.5mg tablet, 4) Zyprexa 10mg tablet | For short term treatment of acute manic episodes associated with Bipolar 1 Disorder. |
| 5)Omniscan 0.5mmol/ml 5ml; 6)Omniscan 0.5mmol/ml 10ml; 7)Omniscan 0.5mmol/ml 15ml; 8)Omniscan 0.5mmol/ml 20ml; 9)Omniscan 0.5mmol/ml 5ml; 10)Omniscan 0.5mmol/ml 10ml; 11)Omniscan 0.5mmol/ml 15ml; 12)Omniscan 0.5mmol/ml 20ml | Use in CNS for children below 6 months of age. |
| 13) Seroxat 20mg tablet | Treatment of post-traumatic Stress Disorder (PTSD) |
| 14) Lamictal Tablets 100mg; 15) Lamictal Tablets 50mg; 16) Lamictal Dispersible 5mg; 17) Lamictal Dispersible 25mg; 18) Lamictal Dispersible 100mg | <p>Adults: Lamictal is indicated for use as monotherapy in the treatment of epilepsy, for partial seizures and generalised seizures, including tonic-clonic seizures.</p> <p>Children: Initial monotherapy treatment in newly diagnosed paediatric patients is not recommended. After epileptic control has been achieved during adjunctive therapy, concomitant anti-epileptic drug(AEDs) may be withdrawn and patients continued on Lamictal monotherapy.</p> |
| 19) MabThera Vial 100mg/10ml; 20) MabThera Vial 500mg/50ml | Treatment of patients with CD20 positive Diffuse Large B-Cell non-Hodgkins Lymphoma (DLCL) in combination with cyclophosphomide , doxorubicin, vincristine and prednisolone (CHOP) chemotherapy. |
| 19) MabThera Vial 100mg/10ml; 20) MabThera Vial 500mg/50ml | For the prophylaxis of acute organ rejection in de novo renal transplantation, in adult patients in combination with long term immunosuppressive triple therapy with ciclosporin,corticosteroids and either azathioprine or mycophenolate mofetil. |
| 21) Simulect Lyophilisate 20mg per vial. | Recommended dose in children for dual therapy In paediatric patients weighing less than 35kg, the |

recommended total dose is 20mg, given in two doses of 10mg each. In paediatric patients weighing 35kg or more, the recommended dose is the adult dose, ie a total dose of 40mg, given in two doses of 20mg each. The first dose should be given within 2 hours prior to transplantation surgery. Simulect must not be administered unless it is absolutely certain that the patient will receive the graft and concomitant immunosuppression. The second dose should be given 4 days after transplantation. The second dose should be withheld if severe hypersensitivity reactions to Simulect or graft loss occur.

DCA 141

| Product (Active Ingredient) | Additional Indication |
|--|--|
| 1) Novantrone 2mg/ml (10mg vial) Injection; 2) Novantrone 2mg/ml (20mg/10ml vial) Injection 3) Novantrone 2mg/ml (25mg/12.5ml vial) Injection. | NOVANTRONE is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses.). NOVANTRONE is not indicated in the treatment of patients with primary progressive multiple sclerosis. |
| 4) Femara 2.5mg Film-coated Tablet | First-line treatment in postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer. |
| 5) Xalatan 0.005% Eye Drops | Reduction of elevated intraocular pressure in patients with chronic angle closure glaucoma (CACG). |
| 6) Recormon 1000 IU; 7) Recormon 2000 IU; 8) Recormon 5000 IU; 9) Recormon 10000 IU; 10) Recormon 50000IU Multidose; 11) Recormon 100000 IU Multidose; 12) Recormon 20000 IU For Reco-Pen 13) Recormon 10000 IU For Reco-Pen. | Treatment of anemia in adult patients with multiple myeloma, low grade non-Hodgkins lymphoma or chronic lymphocytic leukemia, who have a relative erythropoietin deficiency and are receiving anti-tumor therapy. (Deficiency is defined as an inappropriately low serum erythropoietin level in relation to the degree of anemia.) |
| 12) Neupogen 30 Mio 0.30 mg/ml vial; 13) Neupogen 48 Mio 0.48 mg/1.6ml vial; 14) Neupogen Pre-Filled Syringes 30 MU/0.5ml 15) Neupogen Pre-Filled Syringes 48 MU/0.5ml. | Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with exception of chronic myeloid leukemia and myelodysplastic syndromes). Prevention of cytomegalovirus (CMV) disease in solid organ transplant recipients. For the management of acute pain in adults and for the treatment of primary dysmenorrhea. |

| | |
|---|--|
| 16) Cymevene Capsule 250mg. | |
| 17) Celebrex® 100mg Capsule 18) Celebrex® 200mg Capsule. | |

DCA 138

| Product (Active Ingredient) | Additional Indication |
|---|---|
| 1) Fosamax tablet 5 mg 2) Fosamax tablet 10 mg | Fosamax is indicated for treatment of osteoporosis in men to prevent fractures. Fosamax is indicated for treatment and prevention of glucocorticoid induced osteoporosis (GIOP) in men and women. |

DCA 135

| Product (Active Ingredient) | Additional Indication |
|--|--|
| 1) INNOHEP INJ. 20,000 ANTI XA IU/ml (Multidose), 2) INNOHEP INJ. 20,000 Anti XA IU/ml (Prefilled syringe of 0.5 ml) , 3) INNOHEP INJ. 20,000 ANTI XA IU/ml (Prefilled syringe of 0.7 ml), 4) INNOHEP INJ. 20,000 ANTI XA IU/ml (Prefilled syringe of 0.9 ml) | Treatment of pulmonary embolism.. It is not indicated for treatment of serious pulmonary embolism i.e, high risk patients with hemodynamic instability " . |